AFFINIVAX
Affinivax is a biopharmaceutical company developing vaccines used to enhance the depth of protection against infectious diseases. This novel and highly efficient vaccine conjugation technology – named MAPS for Multiple Antigen Presenting System – has the potential to deliver novel vaccines that offer broader disease coverage than existing vaccines, as well as protect against infectious diseases for which there are no effective immunization strategies today. The company is rapidly advancing... a lead program targeting Streptococcus pneumoniae (pneumococcus), a pathogen that is responsible for significant morbidity and mortality in children and adults worldwide. Affinivax was established based on the knowledge and insights of world-leading experts in the fields of infectious diseases and vaccines. The company is backed by an investment from the Bill & Melinda Gates Foundation and has an exclusive license from Boston Children’s Hospital for intellectual property related to the MAPS technology platform.
AFFINIVAX
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2014-06-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.affinivax.com
Total Employee:
51+
Status:
Active
Contact:
617-465-0865
Email Addresses:
[email protected]
Total Funding:
377.49 M USD
Technology used in webpage:
Person Schema Google Google Cloud Gravatar Profiles
Similar Organizations
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Canopy Growth
Canopy Growth is a cannabis consumer product company that manufactures medical cannabis to improve lives.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
Centessa Pharmaceuticals
Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process.
Visby Medical
Visby Medical is a diagnostics company that develops PCR-based diagnostic tests for the detection of infectious diseases.
Esperion
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases.
Insmed
We are a publicly traded (NASDAQ: INSM) biopharmaceutical company dedicated to improving the lives of patients battling serious lung
Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Bausch Health
Bausch Health is a develops and markets medications used in the fields of neurology, dermatology and infectious diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
CARB-X
CARB-X investment in Grant - Affinivax
EcoR1 Capital
EcoR1 Capital investment in Series C - Affinivax
Rock Springs Capital
Rock Springs Capital investment in Series C - Affinivax
Ziff Capital Partners
Ziff Capital Partners investment in Series C - Affinivax
Surveyor Capital
Surveyor Capital investment in Series C - Affinivax
T. Rowe Price
T. Rowe Price investment in Series C - Affinivax
Logos Capital
Logos Capital investment in Series C - Affinivax
Foresite Capital
Foresite Capital investment in Series C - Affinivax
Wellington Management
Wellington Management investment in Series C - Affinivax
Viking Global Investors
Viking Global Investors investment in Series C - Affinivax
Key Employee Changes
| Date | New article |
|---|---|
| 2021-12-16 | Affinivax Appoints Vanya Sagar as Chief People Officer |
| 2021-08-09 | Affinivax Appoints Kara Bickham, MD, as Chief Medical Officer |
Official Site Inspections
http://www.affinivax.com
- Host name: 144.236.160.34.bc.googleusercontent.com
- IP address: 34.160.236.144
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Affinivax"
GSK completes acquisition of Affinivax, Inc.
Aug 16, 2022 GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Affinivax, Inc (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge …See details»
Affinivax Inc. - LinkedIn
Affinivax Inc. | 10,878 followers on LinkedIn. Affinivax was acquired by GSK in August 2022. Affinivax is a clinical stage biotechnology company developing a next generation approach in …See details»
GSK completes acquisition of Affinivax, Inc. | GSK US
Aug 16, 2022 GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Affinivax, Inc (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge …See details»
GSK to acquire clinical-stage biopharmaceutical company …
May 31, 2022 For investors and media only. Issued: 31 May 2022, London UK - LSE announcement. GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development …See details»
GSK completes acquisition of Affinivax, Inc.
Issued: 16 August 2022, London UK GSK completes acquisition of Affinivax, Inc. GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Affinivax, Inc …See details»
GSK completes acquisition of Affinivax, Inc. - PharmiWeb.com
Aug 16, 2022 GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Affinivax, Inc (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge …See details»
Gunderson Dettmer Advises Affinivax, Inc in its $3.3B acquisition …
Affinivax, Inc., a biopharmaceutical company which Gunderson Dettmer has represented since its incorporation, announced on May 31 st that it signed a definitive agreement to be acquired by …See details»
GSK completes acquisition of Affinivax, Inc. – Company …
Aug 16, 2022 The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.See details»
GSK to buy biopharmaceutical company Affinivax
May 31, 2022 GLAXOSMITHKLINE (GSK) has announced it will buy biopharmaceutical company Affinivax, in a deal worth approximately US$3.3bn. Affinivax, which is based in …See details»
GSK will buy vaccine firm Affinivax | C&EN Global Enterprise
Jun 6, 2022 GSK has agreed to buy the vaccine developer Affinivax for $2.1 billion, plus up to $1.2 billion in milestone payments. Affinivax, based in Cambridge, Massachusetts, uses its …See details»
GSK to buy US biotech group Affinivax in $3bn deal - Financial Times
May 31, 2022 GlaxoSmithKline is buying Boston-based biotech Affinivax in a transaction worth up to $3.3bn, bolstering its vaccines business with new technology.See details»
GSK to Acquire Affinivax for Up to $3.3B, Bolstering Vaccine Portfolio
May 31, 2022 GlaxoSmithKline (GSK) has agreed to acquire Affinivax for up to $3.3 billion, in a deal designed to strengthen the buyer’s vaccine portfolio with jabs based on Affinivax’s …See details»
GSK to acquire clinical-stage biopharmaceutical company …
May 31, 2022 GSK plc (LSE/NYSE: GSK) today announced that it has entered into a definitive agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical company …See details»
GSK to Boost Vaccine Portfolio With Affinivax Acquisition
May 31, 2022 GSK plc GSK announced that it has entered into a definitive agreement with Massachusetts-based privately held biopharmaceutical company, Affinivax, Inc., wherein it will …See details»
GSK to spend up to $3.3 bln on Affinivax to boost vaccines roster
May 31, 2022 GSK on Tuesday agreed to buy U.S. biotech Affinivax for up to $3.3 billion, its second major deal in two months, giving the British pharmaceutical giant access to the …See details»
GSK to Buy U.S. Biotech Affinivax in $3.3 Billion Deal
The U.K. drugmaker will make an upfront payment of $2.1 billion for Affinivax and up to $1.2 billion in potential development milestones.See details»
Affinivax, Inc. Company Profile | Cambridge, MA | Competitors ...
Find company research, competitor information, contact details & financial data for Affinivax, Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
GSK wagers $2.1B on Affinivax and its next-generation pneumonia …
May 31, 2022 Through the deal, GSK gets rights to an experimental vaccine known as AFX3722 that's currently in clinical testing for pneumococcal disease, a bacterial infection that’s also …See details»
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine ...
GSK buys Affinivax for up to $3.3 billion, bolstering its vaccine pipeline Nat Rev Drug Discov. 2022 Jul;21(7):480-481. doi: 10.1038/d41573-022-00103-4.See details»
News | Astellas Pharma Inc.
Feb 28, 2022 CAMBRIDGE, Mass, USA, and TOKYO, Japan, February 28, 2022 – Affinivax, Inc. (“Affinivax”) and Astellas Pharma Inc. (“Astellas”) today announced that they have entered …See details»